Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | DRD4 | P21917 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5177912 | 0.96 | KCNH2 (0.65) | KCNH2ADRA1AADRA1BDRD2DRD4 | |
| SCHEMBL5177937 | 0.86 | ADRA1B (0.63) | ADRA1AADRA1BDRD2DRD4DRD3 | |
| SCHEMBL6869328 | 0.86 | DRD2 (0.71) | KCNH2ADRA1BDRD2DRD4DRD3 | |
| SCHEMBL5178130 | 0.86 | ADRA1B (0.62) | ADRA1AADRA1BDRD2DRD4DRD3 | |
| SCHEMBL30767216 | 0.85 | KCNH2 (0.90) | KCNH2DRD2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL6870505 | 0.85 | DRD2 (0.70) | KCNH2ADRA1BDRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL7658247 | 0.84 | KCNH2 (0.88) | KCNH2DRD2SIGMAR1 | |
| SCHEMBL6867106 | 0.83 | DRD2 (0.78) | KCNH2DRD2DRD4DRD3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL7653425 | 0.82 | DRD2 (0.77) | KCNH2DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL5177495 | 0.82 | ADRA1B (0.57) | ADRA1AADRA1BDRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0911330-B1 | 1-(4-Arylpiperazine-1-y1)-3-(2-oxopyrrolidin/piperidin-1-y1) propanes as therapeutic agents for hypertension, ischemia, cardiovascular and other adrenergic receptors related disorders | COUNCIL SCIENT IND RES (IN) | 2007-12-12 | — | — | EP | claimed |
| EP-0913397-B1 | A proces for the synthesis of 1-(4-Arylpiperazine-1-y1)-3-(2-oxypyrrolidin/piperidin-1-yl)propanes as therapeutic agents for hypertension, ischemia, cardiovascular and other adrenergic receptors related disorders | COUNCIL SCIENT IND RES (IN) | 2006-07-05 | — | — | EP | claimed |
| US-6150367-A | 1-(4-ARYLPIPERAZIN-1-YL)-3-(2-OXOPYRROLIDIN-1-YL )PROPANE OR 1-(4-ARYLPIPERAZIN-1-YL)-3-(2-OXOPIPERIDIN-1-YL )PROPANE CAN BE USED AS THERAPEUTIC AGENTS FOR HYPERTENSION, ISCHEMIA, AND OTHER CARDIOVASCULAR DISORDERS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2000-11-21 | — | — | US | claimed |
| EP-0913397-A1 | A proces for the synthesis of 1-(4-Arylpiperazine-1-y1)-3-(2-oxypyrrolidin/piperidin-1-y1) propanes as therapeutic agents for hypertension, ischemia, cardiovascular and other adrenergic receptors related disorders | Council of Scientific and Industrial Research (IN) | 1999-05-06 | — | — | EP | claimed |
| EP-0911330-A1 | 1-(4-Arylpiperazine-1-y1)-3-(2-oxopyrrolidin/piperidin-1-y1) propanes as therapeutic agents for hypertension, ischemia, cardiovascular and other adrenergic receptors related disorders | Council of Scientific & Industrial Research (IN) | 1999-04-28 | — | — | EP | claimed |
| JP-11158143-A | — | — | None | — | — | JP | disclosed |
| EP-0911330-B1 | 1-(4-Arylpiperazine-1-y1)-3-(2-oxopyrrolidin/piperidin-1-y1) propanes as therapeutic agents for hypertension, ischemia, cardiovascular and other adrenergic receptors related disorders | COUNCIL SCIENT IND RES (IN) | 2007-12-12 | — | — | EP | disclosed |
| EP-0913397-B1 | A proces for the synthesis of 1-(4-Arylpiperazine-1-y1)-3-(2-oxypyrrolidin/piperidin-1-yl)propanes as therapeutic agents for hypertension, ischemia, cardiovascular and other adrenergic receptors related disorders | COUNCIL SCIENT IND RES (IN) | 2006-07-05 | — | — | EP | disclosed |
| US-6150367-A | 1-(4-ARYLPIPERAZIN-1-YL)-3-(2-OXOPYRROLIDIN-1-YL )PROPANE OR 1-(4-ARYLPIPERAZIN-1-YL)-3-(2-OXOPIPERIDIN-1-YL )PROPANE CAN BE USED AS THERAPEUTIC AGENTS FOR HYPERTENSION, ISCHEMIA, AND OTHER CARDIOVASCULAR DISORDERS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2000-11-21 | — | — | US | disclosed |
| US-6084097-A | BY CONDENSING A PYRIDYL PIPERAZINE OR A SUBSTITUTED PHENYL PIPERAZINE WITH 1-CHLORO-3-(2-OXOPYRROLIDIN-1-YL)PROPANE OR 1-CHLORO-3-(2-OXOPIPERIDIN-1-YL)PROPANE IN THE PRESENCE OF A BASE, A CATALYST AND ORGANIC SOLVENT; ANTIHYPERTENSIVE AGENTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2000-07-04 | — | — | US | disclosed |
| JP-H11158143-A | 1-(4-ALLYLPIPERAZIN-1-YL)-3-(2-OXO-PYRROLIDIN/PIPERDIN-1-YL)PROPANE USED AS POTENTIAL THERAPEUTIC AGENT FOR HYPERTENSION AND DISEASE RELATED TO ISCHEMIA, CARDIOVASCULAR SYSTEM AND OTHER ADRENALINE RECEPTOR, PRODUCTION OF THE SAME COMPOUND AND TREATMENT OF THE SAME DISEASE USING THE SAME COMPOUND | COUNCIL SCIENT IND RES | 1999-06-15 | — | — | JP | disclosed |
| EP-0913397-A1 | A proces for the synthesis of 1-(4-Arylpiperazine-1-y1)-3-(2-oxypyrrolidin/piperidin-1-y1) propanes as therapeutic agents for hypertension, ischemia, cardiovascular and other adrenergic receptors related disorders | Council of Scientific and Industrial Research (IN) | 1999-05-06 | — | — | EP | disclosed |
| EP-0911330-A1 | 1-(4-Arylpiperazine-1-y1)-3-(2-oxopyrrolidin/piperidin-1-y1) propanes as therapeutic agents for hypertension, ischemia, cardiovascular and other adrenergic receptors related disorders | Council of Scientific & Industrial Research (IN) | 1999-04-28 | — | — | EP | disclosed |